Evidence map›Paper›PMID 31660352›Full record

ArticleOpen forum infectious diseases2019

Eight-Year Experience of Antimicrobial Stewardship Program and the Trend of Carbapenem Use at a Tertiary Acute-Care Hospital in Japan-The Impact of Postprescription Review and Feedback.

Tsubasa Akazawa, Yoshiki Kusama, Haruhisa Fukuda, Kayoko Hayakawa, Satoshi Kutsuna, Yuki Moriyama, Hirotake Ohashi, Saeko Tamura, Kei Yamamoto, Ryohei Hara and 6 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 39 citations in OpenAlex.

  1. Imipenem resistance inNew microbes and new infections · 2026
    Review
  2. Practical and clinical significance of the pharmacist-led antimicrobial stewardship.Journal of pharmaceutical health care and sciences · 2026
    Review
  3. Observational
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Tsubasa AkazawaPharmaceutical Department, National Center for Global Health and Medicine, Tokyo, Japan.
Yoshiki KusamaAMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-7072-2338
Haruhisa FukudaDepartment of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.ORCID 0000-0003-1120-1548
Kayoko HayakawaAMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-5480-4405
Satoshi KutsunaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-6929-8955
Yuki MoriyamaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Hirotake OhashiPharmaceutical Department, National Center for Global Health and Medicine, Tokyo, Japan.
Saeko TamuraDepartment of Clinical Laboratory, National Center for Global Health and Medicine, Tokyo, Japan.
Kei YamamotoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Ryohei HaraPharmaceutical Department, National Center for Global Health and Medicine, Tokyo, Japan.
Ayako ShigenoPharmaceutical Department, National Center for Global Health and Medicine, Tokyo, Japan.
Masayuki OtaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Masahiro IshikaneAMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Shunichiro TokitaPharmaceutical Department, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroyuki TerakadoPharmaceutical Department, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariAMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-4622-8970
National Center for Global Health and Medicine · JPTohoku University · JPKyushu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe implemented a stepwise antimicrobial stewardship program (ASP). This study evaluated the effect of each intervention and the overall economic impact on carbapenem (CAR) use.

methodCarbapenem days of therapy (CAR-DOT) were calculated to assess the effect of each intervention, and antipseudomonal DOT were calculated to assess changes in use of broad-spectrum antibiotics. We carried out segmented regression analysis of studies with interrupted time series for 3 periods: Phase 1 (infectious disease [ID] consultation service only), Phase 2 (adding monitoring and e-mail feedback), and Phase 3 (adding postprescription review and feedback [PPRF] led by ID specialist doctors and pharmacists). We also estimated cost savings over the study period due to decreased CAR use.

resultsThe median monthly CAR-DOT, per month per 100 patient-days, during Phase 1, Phase 2, and Phase 3 was 5.46, 3.69, and 2.78, respectively. The CAR-DOT decreased significantly immediately after the start of Phase 2, but a major decrease was not observed during this period. Although the immediate change was not apparent after Phase 3 started, CAR-DOT decreased significantly over this period. Furthermore, the monthly DOT of 3 alternative antipseudomonal agents also decreased significantly over the study period, but the incidence of antimicrobial resistance did not decrease. Cost savings over the study period, due to decreased CAR use, was estimated to be US $150 000.

conclusionsAdding PPRF on the conventional ASP may accelerate antimicrobial stewardship. Our CAR stewardship program has had positive results, and implementation is ongoing.

Indexed as

antimicrobial resistanceantimicrobial stewardshipcarbapenem; stewardship programcost savingspostprescription review and feedback

Identifiers

PMID31660352
PMCPMC6790398
OpenAlexW2971623638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.